Estrategias antitrombóticas en fibrilación auricular. Registro CONAREC XIX Antithrombotic Strategies in Atrial Fibrillation. The XIX CONAREC Registry

Background: Atrial fibrillation (AF) represents the most common sustained arrhythmia. Treatment has evolved since the last survey performed in our setting, with a marked trend towards the use anticoagulation therapy, and the development of new anticoagulation drugs. However, Argentina lacks updated data about antithrombotic therapy or the use of novel oral anticoagulants (NOAC). Objective: The aim of the study was to assess antithrombotic strategies in AF patients admitted for cardiovascular causes in centers with cardiology residency. Methods: Between September and November 2013, 927 patients with at least one episode of atrial fibrillation within the last 12 months and hospitalized for cardiovascular causes in centers with cardiology residency were enrolled in the study. Results: Median values (interquartile range) of CHADS 2 and CHA 2 DS 2 -VASc and HASBLED scores were: 2 (1-3), 3 (2-4) and 1 (1-2), respectively. At admission, only 54% of patients with history of AF without contraindication and CHADS 2 ≥1 (n=253) received anticoagulation therapy; 89% with dicoumarinic agents and only 26.5% in the therapeutic range. At discharge, anti